{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:34:53Z","timestamp":1749058493820,"version":"3.37.3"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["107-2314-B-075B-002 -MY2"],"award-info":[{"award-number":["107-2314-B-075B-002 -MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0227424","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T13:43:29Z","timestamp":1578663809000},"page":"e0227424","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7557-3370","authenticated-orcid":true,"given":"Wei-Lun","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Shiung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chu","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"pone.0227424.ref001","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1478-3231.2005.01139.x","article-title":"Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia","volume":"25","author":"J.H. Kao","year":"2005","journal-title":"Liver international"},{"key":"pone.0227424.ref002","article-title":"Aasld guidelines for the treatment of hepatocellular carcinoma","author":"J. Heimbach","year":"2017","journal-title":"Hepatology"},{"issue":"suppl 1","key":"pone.0227424.ref003","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"G. Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"pone.0227424.ref004","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/j.gastro.2011.12.062","article-title":"Will Interferon-Free Regimens Prevail?","volume":"142","author":"C. Welsch","year":"2012","journal-title":"Gastroenterology"},{"key":"pone.0227424.ref005","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","article-title":"Anti_Hepatitis C Virus Drugs in Development","volume":"142","author":"Schaefer, eak","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"pone.0227424.ref006","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0227424.ref007","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"M.P. Manns","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"pone.0227424.ref008","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"A.J. Van Der Meer","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"pone.0227424.ref009","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review","volume":"166","author":"O. Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"pone.0227424.ref010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"M.C.M. Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"pone.0227424.ref011","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"I.M. Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0227424.ref012","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"S. Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0227424.ref013","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","article-title":"Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial","volume":"21","author":"M. Omata","year":"2014","journal-title":"J Viral Hepat"},{"issue":"8","key":"pone.0227424.ref014","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/liv.13082","article-title":"A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection","volume":"36","author":"J.H. Kao","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"pone.0227424.ref015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/liv.13206","article-title":"Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials","volume":"37","author":"F. Tacke","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"pone.0227424.ref016","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hepr.13246","article-title":"Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group","volume":"49","author":"T. Akahane","year":"2019","journal-title":"Hepatol Res"},{"issue":"10","key":"pone.0227424.ref017","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1136\/gutjnl-2016-311609","article-title":"HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study","volume":"66","author":"T.M. Welzel","year":"2017","journal-title":"Gut"},{"issue":"4","key":"pone.0227424.ref018","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.12.002","article-title":"Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience","volume":"66","author":"A. Mangia","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0227424.ref019","first-page":"E30","article-title":"Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin","volume":"96","author":"T Kanda","year":"2017","journal-title":"Biology (Basel)"},{"issue":"3","key":"pone.0227424.ref020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0227424.ref021","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/jac\/dkw336","article-title":"Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens","volume":"71","author":"N. Zhou","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"pone.0227424.ref022","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/liv.13069","article-title":"Squillante MM The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin","volume":"36","author":"A. Mangia","year":"2016","journal-title":"Liver Int"},{"key":"pone.0227424.ref023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00535-009-0017-y","article-title":"FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis","volume":"44","author":"J.H. Wang","year":"2009","journal-title":"J Gastroenterol"},{"key":"pone.0227424.ref024","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis patients with HIV\/HCV co-infection","volume":"43","author":"R.K. Sterling","year":"2006","journal-title":"Hepatology"},{"key":"pone.0227424.ref025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"P. Bedossa","year":"1996","journal-title":"Hepatology"},{"issue":"5","key":"pone.0227424.ref026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jcu.1870210502","article-title":"Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study","volume":"21","author":"D.Y. Lin","year":"1993","journal-title":"J Clin Ultrasound"},{"key":"pone.0227424.ref027","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"J.K. Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"pone.0227424.ref028","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"M. Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"pone.0227424.ref029","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0227424.ref030","first-page":"702","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C.Omata M1,2, Kanda T3, Wei L4, Yu ML5, Chuang WL6, Ibrahim A7, Lesmana CR8, Sollano J910","volume":"10","author":"M Kumar","year":"2016","journal-title":"Hepatol Int"},{"issue":"2","key":"pone.0227424.ref031","first-page":"461","article-title":"European Association for the Study of the Liver","volume":"69","author":"EASL Recommendations on Treatment of Hepatitis C 2018","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0227424.ref032","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/apt.13300","article-title":"Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S","volume":"42","author":"L.I. Backus","year":"2015","journal-title":"Veterans. Aliment Pharmacol Ther"},{"key":"pone.0227424.ref033","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"S. Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0227424.ref034","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"G.R. Foster","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0227424.ref035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jfma.2018.09.016","article-title":"Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan","volume":"118","author":"P.N. Cheng","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"pone.0227424.ref036","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan","author":"S.H. Wu","year":"2019","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"pone.0227424.ref037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"P.S. Belperio","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0227424.ref038","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.clinthera.2015.12.017","article-title":"Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison","volume":"38","author":"E. Swallow","year":"2016","journal-title":"Clin Ther"},{"issue":"6","key":"pone.0227424.ref039","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"S.B. Prenner","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0227424.ref040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"L.A. Beste","year":"2017","journal-title":"J Hepatol"},{"key":"pone.0227424.ref041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222605","article-title":"Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviraltreatment failure: a retrospective study with prospectively collected data","author":"Y.H. Yen","year":"2019","journal-title":"Plos one"},{"issue":"5","key":"pone.0227424.ref042","doi-asserted-by":"crossref","first-page":"e026703","DOI":"10.1136\/bmjopen-2018-026703","article-title":"Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study","volume":"9","author":"CF Huang","year":"2019","journal-title":"BMJ Open"},{"key":"pone.0227424.ref043","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/apt.14647","article-title":"Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection","volume":"47","author":"C.H. Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T13:43:43Z","timestamp":1578663823000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227424"}},"subtitle":[],"editor":[{"given":"Wenyu","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0227424","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,1,10]]}}}